N-Zyme Biomedical Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$4.6M
- Investors
-
1
N-Zyme Biomedical General Information
Description
Developer of biopharmaceutical therapeutics designed to treat laryngopharyngeal reflux. The company's technology utilizes a novel class of pepsin inhibitors and reformulated drug delivery systems, including prolonged-release oral formulations and dry powder inhalers, enabling healthcare providers to address non-acidic components of reflux disease and improve treatment outcomes.
Contact Information
Website
www.nzymebio.comCorporate Office
- 905 W Pender Street
- Vancouver, British Columbia V6C 1L6
- Canada
Corporate Office
- 905 W Pender Street
- Vancouver, British Columbia V6C 1L6
- Canada
N-Zyme Biomedical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC (Series A) | 30-Jul-2026 | $4.6M | Completed | Clinical Trials - General |
N-Zyme Biomedical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
N-Zyme Biomedical Patents
N-Zyme Biomedical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025207796-A1 | Methods and compositions for treatment of peptic ulcers and/or peptic ulcer disease | Pending | 26-Mar-2024 | ||
| AU-2023315203-A1 | Sustained-release oral fosamprenavir formulation for treatment of reflux | Pending | 28-Jul-2022 | ||
| EP-4561584-A2 | Sustained-release oral fosamprenavir formulation for treatment of reflux | Pending | 28-Jul-2022 | ||
| US-20240041764-A1 | Sustained-release oral fosamprenavir formulation for treatment of reflux | Pending | 28-Jul-2022 | ||
| WO-2024023583-A2 | Sustained-release oral fosamprenavir formulation for treatment of reflux | Inactive | 28-Jul-2022 | A61K9/0095 |
N-Zyme Biomedical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
N-Zyme Biomedical Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Wild Tree Ventures | Venture Capital | Minority |
N-Zyme Biomedical FAQs
-
When was N-Zyme Biomedical founded?
N-Zyme Biomedical was founded in 2021.
-
Where is N-Zyme Biomedical headquartered?
N-Zyme Biomedical is headquartered in Vancouver, Canada.
-
What is the size of N-Zyme Biomedical?
N-Zyme Biomedical has 5 total employees.
-
What industry is N-Zyme Biomedical in?
N-Zyme Biomedical’s primary industry is Pharmaceuticals.
-
Is N-Zyme Biomedical a private or public company?
N-Zyme Biomedical is a Private company.
-
What is N-Zyme Biomedical’s current revenue?
The current revenue for N-Zyme Biomedical is .
-
How much funding has N-Zyme Biomedical raised over time?
N-Zyme Biomedical has raised $4.6M.
-
Who are N-Zyme Biomedical’s investors?
Wild Tree Ventures has invested in N-Zyme Biomedical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
